M&A Deal Summary |
|
---|---|
Date | 2019-03-11 |
Target | Asterias Biotherapeutics |
Sector | Life Science |
Buyer(s) | Lineage Cell Therapeutics |
Deal Type | Add-on Acquisition |
Advisor(s) | Raymond James - Investment Banking (Financial) Dentons (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 1990 |
Sector | Life Science |
Employees | 68 |
Revenue | 9M USD (2023) |
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. BioTime’s programs are based on the Company’s proprietary cell-based therapy platform which is utilized to develop and manufacture specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury, or administered as a means of helping the body mount an effective immune response to cancer. Lineage Cell Therapeutics was founded in 1990 and is based in Carlsbad, California.
DEAL STATS | # |
---|---|
Overall | 1 of 1 |
Sector (Life Science) | 1 of 1 |
Type (Add-on Acquisition) | 1 of 1 |
State (California) | 1 of 1 |
Country (United States) | 1 of 1 |
Year (2019) | 1 of 1 |